<DOC>
	<DOCNO>NCT02341911</DOCNO>
	<brief_summary>Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin Triple Negative Breast Cancer ( TNBC )</brief_summary>
	<brief_title>Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin Triple Negative Breast Cancer ( TNBC )</brief_title>
	<detailed_description>A Phase II , Single-center , Open-Label , Randomized Study Gemcitabine Plus Cisplatin ( GP ) Versus Gemcitabine Plus Carboplatin ( GC ) First-Line Treatment Patients With Advanced Triple-Negative Breast Cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histological proven unresectable recurrent advance breast cancer , include de novo stage IV disease . 2 . Triplenegative estrogen receptor ( ER ) , progestogen receptor ( PR ) , human epithelial receptor2 ( HER2 ) immunohistochemistry ( ER &lt; 1 % , PR &lt; 1 % Her2 negative ) . A negative Her2 gene amplification verify FISH test patient Her2 ( 2+ ) . For Her2 ( 1+ ) , FISH test might consider investigator . 3 . No prior chemotherapy metastatic breast cancer permit . Prior administration chemotherapy adjuvant/neoadjuvant setting acceptable complete 6 month enrollment . 4 . At least one measurable disease accord response evaluation criterion solid tumor ( RECIST 1.1 ) 5 . Performance status 1 6 . All patient enrol required adequate hematologic , hepatic , renal function 7 . Life expectancy longer 12 week 8 . No serious medical history heart , lung , liver kidney 9 . Be able understand study procedure sign inform consent . 10 . Patients good compliance 1 . Pregnant lactate woman ( female patient childbearing potential must negative serum pregnancy test within 14 day first day drug dosing , , positive , pregnancy rule ultrasound ) 2 . Women childbearing potential , unwilling use adequate contraceptive protection process study 3 . Treatment radiotherapy axial skeleton within 4 week first treatment recovered toxicity previous radiotherapy 4 . Treatment investigational product within 4 week first treatment 5 . Patients symptomatic central nervous system metastasis permit , except stable asymptomatic brain metastasis complete cranial irradiation , least one measurable lesion outside brain . Radiotherapy complete within 4 week prior registration 6 . Other active malignancy ( include hematologic malignancy ) malignancy within last 5 year , except cure nonmelanoma skin cancer cervical intraepithelial neoplasia . 7 . Patients history clinically significant cardiovascular , hepatic , respiratory renal disease , clinically significant hematological endocrinal abnormality , clinically significant neurological psychiatric condition 8 . Uncontrolled serious infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>triple negative breast cancer</keyword>
	<keyword>fine line chemotherapy</keyword>
</DOC>